General
Chiang Mai University Launches Cannabis-Based Pediatric Epilepsy Medication
Chiang Mai University has introduced 'LEPSIA,' a new anti-seizure medication for children derived from cannabis flowers, aiming to reduce treatment costs by 64.8%.
According to a report by Matichon Online, Chiang Mai University (CMU) has officially unveiled 'LEPSIA,' a pharmaceutical product developed to treat pediatric epilepsy. The medication is derived from cannabis flower extracts and is designed to meet international production standards.
For residents and those living in Thailand, this development is significant as it represents a shift toward localized, cost-effective medical solutions. The university claims that the introduction of LEPSIA could reduce the financial burden of epilepsy treatment by approximately 64.8% compared to existing options. By utilizing domestic cannabis resources, the project aims to provide a more accessible alternative for families managing pediatric seizure disorders.
While the announcement highlights the product's adherence to international standards, several details remain to be confirmed. Specifically, the public is awaiting further information regarding the official distribution timeline, the specific clinical settings where the medication will be available, and the regulatory steps required for widespread pharmacy access. As this is a medical development, individuals should consult with qualified healthcare professionals regarding treatment options. SawaLife continues to monitor local reports for updates on when this medication will be integrated into the broader Thai healthcare system.